[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Perceive Biotherapeutics, Inc.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":44},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100522810","phase-1-study-of-voy-101-in-patients-with-advanced-non-neovascular-age-related-macular-degeneration-100522810",false,"NCT06087458","Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration","Phase 1\u002F2a Dose Escalation Study of VOY-101 in Patients With Advanced Non- Neovascular Age-Related Macular Degeneration","JOURNEY","Inclusion Criteria:\n\n* Are ≥60 years of age at the time of consent.\n* Are willing and able to understand and provide written informed consent.\n* Are willing and able to return for scheduled treatment and follow-up examinations.\n* Are able to undergo ETDRS BCDVA testing and ophthalmic imaging.\n* Well-demarcated GA secondary to AMD in the absence of MNV and in the absence of history of MNV for both eyes.\n* Absence of signs of non-exudative MNV.\n* Additional Ocular Inclusion Criteria for both eyes.\n* Meet certain genotype criteria for risk of AMD.\n\nExclusion Criteria:\n\n* Are women of childbearing potential (WOCBP) and are pregnant or unwilling to use and document use of effective contraception for the duration of the study.\n* Additional Systemic, Ocular, and Genetic Exclusion Criteria.","ALL","60 Years",{"count":20,"type":21},60,"ESTIMATED","INTERVENTIONAL",[24,25],"PHASE1","PHASE2","The Phase 1 safety study of VOY-101 comprises of escalating dose Cohorts, followed by a Phase 2a.",[28,29,30],"Age-Related Macular Degeneration","Geographic Atrophy","Non-neovascular AMD","RECRUITING","2025-10-13",{"date":34,"type":35},"2025-10-15","ACTUAL",{"date":37,"type":35},"2023-06-21",{"date":39,"type":21},"2028-03",{"name":41,"class":42},"Perceive Biotherapeutics, Inc.","INDUSTRY",11,""]